Evidence map›Paper›PMID 29520253›Full record

ArticleFrontiers in endocrinology2018

TCF21/POD-1, a Transcritional Regulator of SF-1/NR5A1, as a Potential Prognosis Marker in Adult and Pediatric Adrenocortical Tumors.

Barbara Dos Santos Passaia, Matheus Henrique Dias, Jean Lucas Kremer, Sonir Roberto Rauber Antonini, Madson Queiroz de Almeida, Maria Candida Barisson Villares Fragoso, Claudimara Ferini Pacicco Lotfi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Role of the bHLH transcription factor TCF21 in development and tumorigenesis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021
    Review
  4. Article
  5. TCF21: a critical transcription factor in health and cancer.Journal of molecular medicine (Berlin, Germany) · 2020
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Barbara Dos Santos PassaiaDepartment of Anatomy, Institute of Biomedical Science, University of São Paulo, São Paulo, Brazil.
Matheus Henrique DiasSpecial Laboratory of Applied Toxicology (LETA), Butantan Institute, São Paulo, Brazil.
Jean Lucas KremerDepartment of Anatomy, Institute of Biomedical Science, University of São Paulo, São Paulo, Brazil.
Sonir Roberto Rauber AntoniniDepartment of Pediatrics and Puericulture, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
Madson Queiroz de AlmeidaAdrenal Unit, Hormone and Molecular Genetic Laboratory/LIM42, Hospital of Clinics, School of Medicine, University of São Paulo, São Paulo, Brazil.
Maria Candida Barisson Villares FragosoAdrenal Unit, Hormone and Molecular Genetic Laboratory/LIM42, Hospital of Clinics, School of Medicine, University of São Paulo, São Paulo, Brazil.
Claudimara Ferini Pacicco LotfiDepartment of Anatomy, Institute of Biomedical Science, University of São Paulo, São Paulo, Brazil.
Universidade de São Paulo · BRInstituto Butantan · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With recent progress in understanding the pathogenesis of adrenocortical tumors (ACTs), identification of molecular markers to predict their prognosis has become possible. Transcription factor 21 (TCF21)/podocyte-expressed 1 (POD1) is a transcriptional regulatory protein expressed in mesenchymal cells at sites of epithelial-mesenchymal transition during the development of different systems. Adult carcinomas express less

Indexed as

adrenocortical tumorsadult and pediatric tumorsBUB1BCRISPR/dCas9nuclear receptor subfamily 5 group A member 1podocyte-expressed 1PTEN-induced putative kinase 1transcription factor 21

Identifiers

PMID29520253
PMCPMC5827685
OpenAlexW2793338162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.